Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lonafarnib - Eiger Biopharmaceuticals

Drug Profile

Lonafarnib - Eiger Biopharmaceuticals

Alternative Names: EBP 994; MK-6336; Sarasar; SCH 066336; SCH 66336

Latest Information Update: 20 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Childrens Hospital Boston; Duke University; Eiger BioPharmaceuticals, Inc.; Merck & Co; National Institute of Diabetes and Digestive and Kidney Diseases; Schering-Plough; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Farnesyltranstransferase inhibitors; Protein synthesis inhibitors; Squalene synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Hepatitis D
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis D
  • Phase II Progeria
  • Discontinued Breast cancer; Chronic myelomonocytic leukaemia; Glioblastoma; Glioma; Head and neck cancer; Leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 07 Nov 2019 Eiger BioPharmaceuticals announces intention to submit MAA to EMA for Progeria (Hutchinson-Gilford Progeria Syndrome) and Progeroid laminopathies, in the first quarter of 2020
  • 07 Nov 2019 Eiger BioPharmaceuticals conducts positive pre-NDA and pre-MAA meetings with the US FDA and EMA respectively, for regulatory advancement in Progeria
  • 07 Nov 2019 Efficacy and adverse events data from the phase II LIFT trial in Hepatitis D released by Eiger BioPharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top